If you have a question for our guest, host or DRG please submit it here.
Maximising R+D efforts through better epidemiology understanding
Guest: Mike Hughes, Senior Director of Epidemiology, DRG
In this fireside chat brought to you by Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG, talks to Mike Hughes, Senior Director of Epidemiology at DRG. With epidemiology entering our daily vernacular, thanks to the Covid-19 pandemic, Mike gives a definition of what it is, the approaches used to model epidemiology associated with diseases and how it’s beneficial across all stages of research and development in pharma. In particular, they talk about the value epidemiology can bring to decision making and how it can aid in maximizing R&D efforts and investment decisions surrounding pipeline development and go to market plans. Watch the full interview here.
About our Guest
Mike Hughes, Senior Director of Epidemiology, DRG
Dr. Hughes has expertise in systematic literature reviews and meta-analysis, cancer epidemiology and patient flow modelling of cancer and chronic non-communicable diseases.
He has previously worked on behalf of the National Institute for Health and Care Excellence (NICE), as well as other professional organizations, in the development of clinical guidelines.
Dr. Hughes has an MSc in artificial intelligence from Brunel University and received his first Ph.D. in measurement and information in medicine from City University, London in 2004. He received his second Ph.D. in the foundations of chance and probability theory from the University of Nottingham in 2020.
About our Host
Mike Ward, Head of Thought Leadership, DRG
Mike Ward serves as Global Head of Thought Leadership at Decision Resources Group (DRG), part of Clarivate. As both a journalist and analyst, Mike has been writing, analyzing and commenting on the life sciences industry for more than 35 years. He has held editorial and content leadership roles at various publications and organizations across the industry.